EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische StudieOpen Access · CC BY 4.0

One‐year outcomes of pulmonary vein isolation with a novel cryoballoon: Primary results of the FROZEN AF trial

Kenneth A Ellenbogen, Suneet Mittal, Niraj Varma iD, Arash Aryana iD, Nassir Marrouche iD, Ante Anić, Devi Nair, Jean Champagne, Saverio Iacopino iD, Carlo de Asmundis, Stanislav Weiner, Kevin Makati und 3 weitere

Journal of Cardiovascular Electrophysiology · 2024-04 · 35 (4) · 832-842

DOI: 10.1111/jce.16220 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Cardiovascular Electrophysiology, online erschienen am 06.03.2024. Verfasst von Kenneth A Ellenbogen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Virginian Commonwealth University, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Cryosurgery, Heart Injuries. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boston Scientific Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cryoablation therapy for pulmonary vein isolation (PVI) to treat paroxysmal atrial fibrillation (PAF) is well established. A novel 28 mm cryoballoon system designed to operate under low pressure to safely reach a lower nadir temperature and maintain constant balloon size during cooling has not been prospectively studied in a large patient population for safety and efficacy. The FROZEN AF (NCT04133168) trial was an international multicenter, open‐label, prospective, single‐arm study on the safety and performance of a novel cryoballoon system for treatment of PAF. Methods and Results The study enrolled patients at 44 sites in 10 countries across North America, Europe, and Asia. Subjects were indicated for PVI treatment of PAF and had failed or were intolerant of one or more antiarrhythmic drugs. Procedural outcomes were defined based on the 2017 HRS consensus statement. Follow‐up was performed at 7 days, 3, 6, and 12 months. Data are reported as mean ± SD or median (IQR). PVI was performed with a 28 mm cryoballoon in 325 drug refractory PAF patients. Complete PVI was achieved in 95.7% of patients. In cryoablation lesions longer than 60 s, 60.1% of PV isolations required only a single cryoballoon application. Procedure related complications included: phrenic nerve palsy [temporary 4 (1.2%), persistent 0 (0.0%)], cardiac tamponade/perforation 2 (0.6%), and air embolism 1 (0.3%). Freedom from documented atrial arrhythmia recurrence at 12 months was 79.9% (AF 82.7%, AFL 96.5%, AT 98.1%), antiarrhythmic drugs (AAD) were continued or re‐initiated in 26.8% of patients after the 3‐month blanking period. Additionally, an extension arm enrolled 50 pts for treatment with 28/31 mm variable size cryoballoon. A single temporary PNP occurred in this group, which resolved before discharge. Freedom from documented recurrence at 12 months in these pts was 82.0%.

Conclusions

This novel cryoballoon may facilitate PVI to treat PAF, providing more options to address the variety of anatomies present in patients with PAF. This cryoballoon system proved to be safe and effective for treatment of patients with drug refractory or drug intolerant PAF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationCatheter AblationCryosurgeryHeart InjuriesPulmonary VeinsHumansAnti-Arrhythmia AgentsProspective StudiesRecurrenceTreatment Outcome

Stichwörter der Autor:innen

atrial arrhythmiasatrial fibrillationcryoballoon ablation

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • Division of Cardiology, Virginian Commonwealth University, Richmond, Virginia, USA.
  • Valley Hospital, Ridgewood, New Jersey, USA.
  • Cleveland Clinic, Cleveland, Ohio, USA.
  • Mercy General Hospital, Sacramento, California, USA.
  • Tulane University School of Medicine, New Orleans, Louisiana, USA.
  • University Hospital Split, Split, Croatia.

ORCID-Profile: Niraj Varma, Arash Aryana, Nassir Marrouche, Saverio Iacopino, Wilber Su

Förderung

  • Boston Scientific Corporation

Zitieren

APA

Ellenbogen, K. A., Mittal, S., Varma, N., Aryana, A., Marrouche, N., Anić, A., Nair, D., Champagne, J., Iacopino, S., de Asmundis, C., Weiner, S., Makati, K., Raybuck, J. D., Richards, E., & Su, W. (2024). One‐year outcomes of pulmonary vein isolation with a novel cryoballoon: Primary results of the FROZEN AF trial. Journal of Cardiovascular Electrophysiology, 35(4), 832-842. https://doi.org/10.1111/jce.16220

Vancouver

Ellenbogen KA, Mittal S, Varma N, Aryana A, Marrouche N, Anić A, et al. One‐year outcomes of pulmonary vein isolation with a novel cryoballoon: Primary results of the FROZEN AF trial. Journal of Cardiovascular Electrophysiology. 2024;35(4):832-842. doi:10.1111/jce.16220

BibTeX
@article{Ellenbogen2024,
  author = {Ellenbogen, Kenneth A and Mittal, Suneet and Varma, Niraj and Aryana, Arash and Marrouche, Nassir and Anić, Ante and Nair, Devi and Champagne, Jean and Iacopino, Saverio and de Asmundis, Carlo and Weiner, Stanislav and Makati, Kevin and Raybuck, Jonathan D and Richards, Elizabeth and Su, Wilber},
  title = {One‐year outcomes of pulmonary vein isolation with a novel cryoballoon: Primary results of the FROZEN AF trial},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2024},
  volume = {35},
  number = {4},
  pages = {832--842},
  doi = {10.1111/jce.16220}
}
Kostenlos starten →